Abstract
Traumatic injury to the central nervous system is an important public health problem. Severe head and spinal cord injuries are a major cause of disability and death, particularly among young adults. The medical sequelae of central nervous system injury are substantial, resulting in large demands upon the patient’s family, the health care system, and society in general. The National Head and Spinal Cord Injury Survey estimates the rate of occurrence of severe head injury at 200 per 100000 (Kraus et al. 1996). Motor vehicle accidents are the primary cause of both brain and spinal cord injury, and young healthy males are the primary victims.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alves WM, Eisenberg HM (1996) Head Injury Trials-Past and Present. In: Narayan RK, Wilberger JE Jr, Povlishock JT (eds) Neurotrauma. McGraw-Hill, New York, pp 946–967
Bardt TF, Unterberg AW, Kiening KL, Schneider GH, Lanksch WR (1998) Multimodal cerebral monitoring in comatose head-injured patients. Acta Neurochir (Wien) 140:357–365
Bracken MB, Collins WF, Freeman DF, Shepard MJ, Wagner FW, Silten RM, Hellenbrand KG, Ransohoff J, Hunt WE, Perot PL Jr et al. (1984) Efficacy of methylprednisolone in acute spinal cord injury. JAMA 251:45–52
Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo Summers L, Maroon J et al. (1990) A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 322:1405–1411
Bracken MB, Shepard MJ, Holford TR, Leo Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL Jr, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W (1997) Administration of methylprednisolone for 24 or 48h or tirilazad mesylate for 48h in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 277:1597–1604
Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R et al. (1992) Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90min. Stroke 23:632–640
Bullock R, Chesnut RM, Clifton G, Ghajar J, Marion DW, Narayan RK, Newell DW, Pitts LH, Rosner MJ, Wilberger JW (1996) Guidelines for the management of severe head injury. Brain Trauma Foundation. Eur J Emerg Med 3:109–127
Bullock R, Zauner A, Woodward JJ, Myseros J, Choi SC, Ward JD, Marmarou A, Young HF (1998) Factors affecting excitatory amino acid release following severe human head injury. J Neurosurg 89:507–518
Chesnut RM, Marshall SB, Piek J, Blunt BA, Klauber MR, Marshall LF (1993) Early and late systemic hypotension as a frequent and fundamental source of cerebral ischemia following severe brain injury in the Traumatic Coma Data Bank. Acta Neurochir Suppl (Wien) 59:121–125
Chesnut RM (1997) Avoidance of hypotension: conditio sine qua non of successful severe head-injury management. J Trauma 42:S4–S9
Choi SC, Ward JD, Becker DP (1983) Chart for outcome prediction in severe head injury. J Neurosurg 59:294–297
Choi SC, Narayan RK, Anderson RL, Ward JD (1988) Enhanced specificity of prognosis in severe head injury. J Neurosurg 69:381–385
Choi SC, Germanson TP, Barnes TY (1995) A simple measure in defining optimal strata in clinical trials. Control Clin Trials 16:164–171
Choi SC, Barnes TY (1996) Predicting Outcome in the Head Injured Patient. In: Narayan RK, Wilberger JE Jr, Povlishock JT (eds) Neurotrauma. McGraw-Hill, New York, pp 779–792
Choi SC, Marmarou A, Bullock R, Nichols J, Wei X, Pitts L, The American Brain Injury Consortium Study Group (1998) Primary endpoints in phase III clinical trials of severe head trauma: DRS versus GOS. J Neurotrauma 15:771–776
Clifton GL, Hayes RL, Levin HS, Michel ME, Choi SC (1992) Outcome measures for clinical trials involving traumatically brain-injured patients: report of a conference. Neurosurgery 31:975–978
Doppenberg EM, Bullock R (1997) Clinical neuro-protection trials in severe traumatic brain injury: lessons from previous studies. J Neurotrauma 14:71–80
Fleishaker JC, Pearson LK, Peters GR (1998) Induction of tirilazad clearance by Phenytoin. Biopharm Drug Dispos 19:91–96
Gaetani P, Tancioni F, Tartara F, Carnevale L, Brambilla G, Mille T, Rodriguez y Baena R (1995) Prognostic value of the amount of posttraumatic subarachnoid haemorrhage in a six month follow up period. J Neurol Neurosurg Psychiatry 59:635–637
Gennarelli TA, Spielman GM, Langfitt TW, Gildenberg PL, Harrington T, Jane JA, Marshall LF, Miller JD, Pitts LH (1982) Influence of the type of intracranial lesion on outcome from severe head injury. J Neurosurg 56:26–32
Ghajar J, Hariri RJ, Narayan RK, Iacono LA, Firlik K, Patterson RH (1995) Survey of critical care management of comatose, head-injured patients in the United States. Crit Care Med 23:560–567
Haley EC Jr, Kassell NF, Apperson Hansen C, Maile MH, Alves WM (1997) A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg 86:467–474
Hall ED (1992) The neuroprotective pharmacology of methylprednisolone. J Neurosurg 76:13–22
Hamilton BB, Granger CV, Sherwin FS (1987) A uniform national data system for medical rehabilitation. In: Fuhrer MJ (ed) Rehabilitation Outcomes: Analysis and Measurement. Brooks, Baltimore, pp 137–147
Hayes RL, Dixon CE (1994) Neurochemical changes in mild head injury. Semin Neurol 14:25–31
Jennett B, Bond M (1975) Assessment of outcome after severe brain damage. Lancet 1:480–484
Jennett B, Snoek J, Bond MR, Brooks N (1981) Disability after severe head injury: observations on the use of the Glasgow Outcome Scale. J Neurol Neurosurg Psychiatry 44:285–293
Kassell NF, Haley EC Jr, Apperson Hansen C, Alves WM (1996) Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. J Neurosurg 84:221–228
Kraus JF, McArthur DL, Silverman TA, Jayaraman M (1996) Epidemiology of Brain Injury. In: Narayan RK, Wilberger JE Jr, Povlishock JT (eds) Neurotrauma, vol 1. McGraw-Hill, New York, pp 13–30
Levin HS, High WM, Goethe KE, Sisson RA, Overall JE, Rhoades HM, Eisenberg HM, Kalisky Z, Gary HE (1987) The neurobehavioural rating scale: assessment of the behavioural sequelae of head injury by the clinician. J Neurol Neurosurg Psychiatry 50:183–193
Maas AI, Dearden M, Teasdale GM, Braakman R, Cohadon F, Iannotti F, Karimi A, Lapierre F, Murray G, Ohman J, Persson L, Servadei F, Stocchetti N, Unterberg A (1997) EBIC-guidelines for management of severe head injury in adults. European Brain Injury Consortium. Acta Neurochir (Wien) 139:286–294
Marmarou A (1996) Conduct of head injury trials in the United States: the American Brain Injury Consortium (ABIC). Acta Neurochir Suppl (Wien) 66:118–121
Marmarou A, Nichols J, Burgess J, Newell D, Troha J, Burnham D, Pitts L, The American Brain Injury Consortium Study Group (1999) Effects of the bradykinin antagonist Bradycor (Deltibant, CP-1027) in severe brain injury: results of a multi-center, randomized, placebo-controlled trial. In Press
Marshall LF, Becker DP, Bowers SA, Cayard C, Eisenberg H, Gross CR, Grossman RG, Jane JA, Kunitz SC, Rimel R, Tabaddor K, Warren J (1983) The National Traumatic Coma Data Bank. Part 1: Design, purpose, goals, and results. J Neurosurg 59:276–284
Marshall LF, Maas AI, Marshall SB, Bricolo A, Fearnside M, Iannotti F, Klauber MR, Lagarrigue J, Lobato R, Persson L, Pickard JD, Piek J, Servadei F, Wellis GN, Morris GF, Means ED, Musch B (1998) A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J Neurosurg 89:519–525
Mcintosh TK, Juhler M, Wieloch T (1998) Novel pharmacologic strategies in the treatment of experimental traumatic brain injury: 1998. J Neurotrauma 15:731–769
NINDS rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587
Rappaport M, Hall KM, Hopkins K, Belleza T, Cope DN (1982) Disability rating scale for severe head trauma: coma to community. Arch Phys Med Rehabil 63:118–123
Sandage BW (1998) Balancing phase II and III efficacy trials. Drug Inf J 32:977–980
Scheibel RS, Levin HS, Clifton GL (1998) Completion rates and feasibility of outcome measures: experience in a multicenter trial of systemic hypothermia for severe head injury. J Neurotrauma 15:685–692
Teasdale GM, Braakman R, Cohadon F, Dearden M, Iannotti F, Karimi A, Lapierre F, Maas A, Murray G, Ohman J, Persson L, Servadei F, Stocchetti N, Trojanowski T, Unterberg A (1997) The European Brain Injury Consortium. Nemo solus satis sapit: nobody knows enough alone. Acta Neurochir (Wien) 139:797–803
Teasdale GM, Pettigrew L, Wilson JT, Murray G, Jennett B (1998) Analyzing outcome of treatment of severe head injury: a review and update on advancing the use of the Glasgow Outcome Scale. J Neurotrauma 15:587–597
Teasdale GM, Graham DI (1998) Craniocerebral trauma: protection and retrieval of the neuronal population after injury. Neurosurgery 43:723–737
Toulmond S, Serrano A, Benavides J, Scatton B (1993) Prevention by eliprodil (SL 82.0715) of traumatic brain damage in the rat. Existence of a large (18h) therapeutic window. Brain Res 620:32–41
Wichman A, Sandler AL (1997) Research involving critically ill subjects in emergency circumstances: new regulations, new challenges. Neurology 48:1151–1155
Wilson JT, Pettigrew L, Teasdale GM (1998) Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma 15:573–585
Young B, Runge JW, Waxman KS, Harrington T, Wilberger J, Muizelaar JP, Boddy A, Kupiec JW (1996) Effects of pegorgotein on neurologic outcome of patients with severe head injury. A multicenter, randomized controlled trial. JAMA 276:538–543
Zivin JA (1998) Factors determining the therapeutic window for stroke. Neurology 50:599–603
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Poole, R.M. (2002). Traumatic Central Nervous System Injury. In: Marcoux, F.W., Choi, D.W. (eds) CNS Neuroprotection. Handbook of Experimental Pharmacology, vol 155. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-06274-6_14
Download citation
DOI: https://doi.org/10.1007/978-3-662-06274-6_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-07625-1
Online ISBN: 978-3-662-06274-6
eBook Packages: Springer Book Archive